Gregory Naeve joined Bellicum in August 2017 as Chief Business Officer to lead product and portfolio strategy as well as business development for the Company. Previously, Dr. Naeve served as the ImmunoOncology & Cell Therapy Lead for Pfizer’s External Research and Development Unit. During his tenure, he was a key member of the executive team responsible for identifying and implementing many of the strategic partnerships in Pfizer’s ImmunoOncology portfolio, including the Cellectis and Servier CAR T alliances. Prior to Pfizer, Dr. Naeve served as Principal of The Column Group, a venture capital firm focused on investing in and creating innovative biotechnology companies. Prior to that, he was the President and Chief Scientific Officer at Parallax Biosystems, a company he co-founded that developed novel technologies with applications in preclinical drug discovery and diagnostics. Early in his career, Dr. Naeve held research positions at Neurocrine Biosciences and Amgen. Dr. Naeve earned his Ph.D. in Biochemistry from the University of Southern California and his B.S. in Biochemistry and Biological Sciences from Colorado State University.